[Effect of recombinant human soluble thrombomodulin in patients with solid carcinoma with DIC].
There are only a few reports in the literature about the effect of recombinant human soluble thrombomodulin (rTM) in patients with solid carcinoma with disseminated intravascular coagulation (DIC). A retrospective study of 40 patients with solid carcinoma with DIC was performed between February 2009 and April 2013. The withdrawal rate was 32.5% (13/40 patients), and the 28-day survival rate was 40.0% (16/40 patients). Patients with successful withdrawal of DIC had significantly better outcomes (p<.001). Therapy with rTM is one of the treatment options for patients with solid carcinoma with DIC.
Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
Yuka
Y
Asano
Shinichiro
S
Kashiwagi
Masatsune
M
Shibutani
Sadaaki
S
Yamazoe
Satoru
S
Noda
Katsunobu
K
Sakurai
Hisashi
H
Nagahara
Kenjiro
K
Kimura
Hidemi
H
Kawajiri
Takahiro
T
Toyokawa
Ryosuke
R
Amano
Naoshi
N
Kubo
Hiroaki
H
Tanaka
Kazuya
K
Muguruma
Hiroshi
H
Ohtani
Tsutomu
T
Takashima
Masakazu
M
Yashiro
Naoyoshi
N
Onoda
Kiyoshi
K
Maeda
Masaichi
M
Ohira
Kosei
K
Hirakawa
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D012995:Solubility; D018180:Thrombomodulin / Q000627:therapeutic use*
D011994:Recombinant Proteins; C546931:THBD protein, human; D018180:Thrombomodulin